BLRD Research Career Scientist Award Application

BLRD 研究职业科学家奖申请

• 批准号: 10471518
• 负责人: Michal A Olszewski
• 金额: --
• 依托单位: VETERANS HEALTH ADMINISTRATION
• 依托单位国家: 美国
• 财政年份: 2022
• 资助国家: 美国
• 起止时间: 2022-04-01 至 2027-03-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10471518
• 关键词: Acquired Immunodeficiency Syndrome; Acute Respiratory Distress Syndrome; Animal Model; Antibiotic Therapy; Antibody Therapy; Antifungal Agents; Area; Autoimmune Diseases; Award; Bioinformatics; Brain; COVID-19 pandemic; COVID-19 patient; COVID-19/ARDS; CXCR3 gene; Caliber; Cause of Death; Cerebrum; Chronic lung disease; Clinical Data; Clinical Research; Code; Collaborations; Communicable Diseases; Communities; Complement; Cryptococcosis; Cryptococcus; Cryptococcus neoformans; Death Domain; Dendritic Cells; Dendritic cell activation; Development; Disease; Drug resistance; Drug toxicity; Effectiveness; Epigenetic Process; Exhibits; Exposure to; Foundations; Funding; Future; Genes; Genetic Transcription; Goals; Grant; HIV; Healthcare; Host Defense; Host Defense Mechanism; Human; Hypersensitivity; Immune; Immune Evasion; Immune response; Immune system; Immunity; Immunocompetent; Immunocompromised Host; Immunologics; Immunologist; Immunology; Immunotherapeutic agent; Immunotherapy; Individual; Infection; Inflammation; Inflammatory; Integration Host Factors; Interleukin-10; Intervention; Knowledge; Location; Lung; Lung infections; Malignant Neoplasms; Mentors; Microbe; Modification; Molecular; Morbidity - disease rate; Mycoses; National Institute of Allergy and Infectious Disease; Organ Transplantation; Organism; Outcome; Pathogenesis; Pathologic; Pathology; Pathway interactions; Patients; Phenotype; Process; Publications; Published Comment; Publishing; RIPK3 gene; Receptor Signaling; Regimen; Research; Resistance development; Risk; Risk Factors; Role; SARS-CoV-2 infection; Science; Scientist; Services; Signal Pathway; Signal Transduction; Site; Source; Substance abuse problem; T cell response; T-Lymphocyte; TNF gene; Testing; Therapeutic; Toxic effect; Transplant Recipients; United States National Institutes of Health; Validation; Veterans; Virulence Factors; Work; antimicrobial; career; chronic infection; cytokine; design; editorial; experience; fungus; global health; high risk; human data; immunomodulatory therapies; immunopathology; immunoregulation; interest; microbial; microorganism interaction; military service; monocyte; mortality; mouse model; mutant; neglect; neutrophil; novel therapeutics; novel vaccines; pathogen; patient population; pre-clinical; prevent; programs; response; risk stratification; scavenger receptor; stem; therapeutic target; translational study; tumor; vaccine strategy

Dr. Olszewski is an immunologist with over 25 years of experience in studies of inflammatory/infectious diseases in the lungs, CNS and at the systemic level with over 20 years of research at the Ann Arbor VAHS. Overall career goal is to expand the understanding of host pathogen interactions, specifically the effect of microbe- and host-derived signals on the fate of the immune response. Understanding of these interactions will create a foundation for the development of safe and effective immunomodulatory therapies that will greatly enhance the effectiveness of antimicrobial therapeutics in persistent infections. Nominee’s lab has specialized in animal modeling and translational studies, applying these principles to a broader range of diseases as shown by more recent clinical data. His studies have mostly focused on host pathogen interactions between invasive fungus C. neoformans and the mammalian immune system. The studies of invasive fungal infections are of specific interest to the VA, because of the higher than average rate of immunocompromised patients among veterans and increased risk of exposure to various endemic and environmental fungi due to locations and conditions of military service that favor fungal exposures. Unfortunately, the invasive fungal infections have unacceptably high mortality rates, due to limited effectiveness of antifungal drugs, toxicity, and the high potential of fungal organisms to develop resistance to these drugs. Thus, it is crucial to understand the effects of immunomodulation on fungal disease from the perspective of the natural mechanisms of host defenses, mechanisms of immune evasion exhibited by fungi, and to explore pre-clinical approaches of immunomodulatory therapies. The long-standing support of VA BLR&D was one of the crucial factors that allowed our group to establish itself among leaders in cryptococcal and fungal immunology. Additional areas of work involve clinical studies looking into pathogenesis od ARDS in COVID19 patients and infections of GI track. The VA RCS Award will allow the nominee to continue his productive research career, successful mentoring of new scientists and to provide service to the research community at the VA and beyond.

Olszewski 博士是一位免疫学家，拥有超过 25 年的研究经验 肺部、中枢神经系统和全身炎症/感染性疾病超过20年 安娜堡 VAHS 的研究总体目标是扩大对主持人的了解。 病原体相互作用，特别是微生物和宿主来源的信号对病原体命运的影响 了解这些相互作用将为免疫反应奠定基础。 开发安全有效的免疫调节疗法将大大增强 被提名者的实验室已证实抗菌疗法对持续性感染的有效性。 专门从事动物建模和转化研究，将这些原则应用到更广泛的领域 最近的临床数据显示了一系列疾病。 他的研究主要集中在入侵真菌 C. 之间的宿主病原体相互作用。 新型隐球菌和哺乳动物免疫系统的研究包括侵袭性真菌感染。 VA 特别感兴趣，因为免疫功能低下的比率高于平均水平 退伍军人中的患者以及接触各种流行病和环境的风险增加 由于服兵役的地点和条件有利于真菌暴露，因此出现真菌感染。 不幸的是，侵袭性真菌感染的死亡率高得令人无法接受，原因是 抗真菌药物的有效性有限、毒性以及真菌生物体的高潜力 因此，了解这些药物的作用至关重要。 从宿主自然机制角度探讨真菌病的免疫调节 防御，真菌表现出的免疫逃避机制，并探索临床前 VA BLR&D 的长期支持就是其中之一。 使我们的团队跻身隐球菌领域领导者行列的关键因素 其他工作领域包括研究发病机制的临床研究。 od 新冠肺炎患者的 ARDS 和胃肠道感染 VA RCS 奖将允许 被提名人将继续他富有成效的研究生涯，成功指导新科学家和 为 VA 及其他地区的研究界提供服务。